Alzheimer's and Parkinson's Diseases: Expected Economic Impact on Europe-A Call for a Uniform European Strategy
Language English Country United States Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
27567862
DOI
10.3233/jad-160484
PII: JAD160484
Knihovny.cz E-resources
- Keywords
- Alzheimer’s disease, Europe, Parkinson’s disease, costs, economic burden,
- MeSH
- Alzheimer Disease drug therapy economics epidemiology MeSH
- Humans MeSH
- Mortality trends MeSH
- Neuroprotective Agents therapeutic use MeSH
- Cost of Illness * MeSH
- Parkinson Disease drug therapy economics epidemiology MeSH
- Retrospective Studies MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Geographicals
- Europe epidemiology MeSH
- Names of Substances
- Neuroprotective Agents MeSH
The purpose of this study is to analyze the economic burden of persons with Alzheimer's disease (AD) and Parkinson's disease (PD) in Europe. On the basis of available data about the number of persons with dementia, their prevalence, and treatment and care costs, a mean cost burden is estimated for the year of 2030 and for the year of 2050 in Europe. The method of retrospective analysis of available sources was used; furthermore, analysis of database data such as WHO and Eurostat, which provide information about the number of older people and people with dementia; and specification of direct and indirect medical and nonmedical costs of patients with AD and PD from current studies was also used. The findings of this study confirm that the number of patients affected with AD and PD, as well as annual costs of the treatment and care of these patients, in the selected European countries are rapidly growing. The cost burden of both AD and PD in the selected European countries rises year by year, and by 2050, the cost burden of both diseases in fact will be almost two times higher in comparison with the year of 2010. In 2050, the overall mean cost burden is estimated to reach 357 billion Euros. The European Union calls for a joint initiative in the development of a uniformed strategic plan in the fight against dementia.
Biomedical Research Center University Hospital Hradec Kralove Hradec Kralove Czech Republic
Biomedical Research Centrum University Hospital Hradec Kralove Hradec Kralove Czech Republic
Faculty of Informatics and Management University of Hradec Kralove Hradec Kralove Czech Republic
References provided by Crossref.org
Effectiveness of the dog therapy for patients with dementia - a systematic review
Nitrendipine and Dementia: Forgotten Positive Facts?
The direct costs of multiple sclerosis-study in the Czech Republic
Economic analysis of acupuncture for migraine prophylaxis
Technological Solutions for Older People with Alzheimer's Disease: Review
PPI Long Term Use: Risk of Neurological Adverse Events?
Development of 2-Methoxyhuprine as Novel Lead for Alzheimer's Disease Therapy
